Actively Recruiting
Evaluation of Evero Everolimus-Coated Balloon Versus Paclitaxel-Coated Balloons for Femoropopliteal Artery Disease
Led by Cook Research Incorporated · Updated on 2026-11-04
410
Participants Needed
15
Research Sites
213 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the long-term safety and effectiveness of the Advance Evero18 Everolimus-coated Percutaneous Transluminal Angioplasty Balloon Catheter Evero drug-coated balloon, DCB compared to paclitaxel drug-coated balloons in patients with peripheral arterial disease PAD affecting the femoropopliteal artery. The study is a randomized controlled trial designed to demonstrate that the Evero DCB is not inferior in safety and effectiveness to commercially available paclitaxel DCBs. Participants will be treated with either the Evero DCB or a commercially available paclitaxel-coated balloon to provide local treatment to de novo or restenotic lesions in the native superficial femoral and popliteal arteries. The treatments involve percutaneous transluminal angioplasty PTA using these drug-coated balloons applied directly to the affected arteries. During the study, participants will be monitored for safety endpoints such as death within 30 days, and amputation or clinically driven target lesion revascularization CD-TLR within 12 months. Effectiveness will also be evaluated at 12 months. Participants will undergo follow-up assessments according to the study schedule to measure these outcomes, with the trial expected to complete by October 2032.
CONDITIONS
Brief Title
EVERO Drug-coated Balloon (DCB) Randomized Trial
Research Team
N
Noah Shields
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here